Human Papillomavirus Vaccine

For more information, s. Human papillomavirus (HPV) ACIP Vaccine Recommendations. Preparations Two vaccines are available: A quadruple vaccine (HPV4), which protects against four types of HPV: types 6 and 11 that cause> 90% of visible genital warts, and types 16 and 18, which cause most cases of cervical cancer a bivalent vaccine (HPV2), which protects against types 16 and 18 Both vaccines can be used in women; HPV4 is used in men. Recombinant DNA technology is used to both vaccines from the major capsid protein (L1) of the HPV manufacture. The L1 proteins self-assemble into non-infectious, non-oncogenic virus-like particles (VLPs). A new vaccine that is effective against nine types of HPV, will be available soon. The new vaccine covers the same types of HPV as the quadrivalent vaccine and also offers protection against HPV types 31, 33, 45, 52 and 58, which extends the protection against HPV-related cancers. Indications The HPV vaccine is a routine childhood vaccination (see Table: Recommended vaccination schedule for the age of 7-18 years). HPV4 or HPV2 is recommended for women aged 11 or 12 years and for women up to the age of 26 if they have not been vaccinated previously. HPV4 is for men aged 11 or 12 years and not previously until the age of 26 years recommended vaccinated men; HPV4 is recommended for all men who are in this age group and have sex with men. Vaccination is recommended for all persons who are immunocompromised, including HIV patients, up to the age of 26 if they have not been vaccinated at a younger age. Contraindications and precautions The contraindications include a severe allergic reaction (eg., Anaphylaxis) after a previous dose or to a vaccine component pregnancy Although the HPV vaccines are not recommended for pregnant women, no pregnancy test is required prior to vaccination. When pregnancy is detected after vaccination series was begun, no action is required, but the remaining boxes of the series should be delayed until the pregnancy is over. The most important precaution is Moderate or severe acute illness with or without fever (vaccination, if possible, be postponed until the disease is over) Dosage and Administration The dose is 0.5 ml i.m. and is administered at 0 months, at 2 months and 6 months in a group of 3 doses. Undesirable effects serious side effects have been reported. To the weak side effects include pain, redness, swelling and tenderness at the injection site.

Health Life Media Team

Leave a Reply